Incyte reports Q3 2026 loss but revenue beat and raises full‑year sales outlook
+1 new source since this summary was written
Incyte Corp. posted a GAAP net loss of $784.8 million, or $3.86 per diluted share, for the third quarter of 2026, while revenue rose 14% year‑over‑year to $1.56 billion. The loss was driven by a one‑time R&D charge from the Vega Therapeutics acquisition. The company also lifted its 2026 total net‑sales guidance to a range of $5.21 billion‑$5.30 billion.
Why it matters
The revenue beat and higher sales outlook may support the stock despite the larger loss, as analysts will reassess valuation based on the updated guidance (the company raised its outlook). The one‑time charge is non‑recurring, so future quarters could show improved profitability.
Key facts
- 1GAAP net loss was $784.8 million, or $3.86 per diluted share. tradingview.com
- 2Revenue for Q3 2026 was $1.56 billion, up 14% year‑over‑year. tradingview.com
- 3Non‑GAAP diluted loss per share was $3.60. seekingalpha.com
- 4Full‑year 2026 total net‑sales guidance was raised to $5.21 billion‑$5.30 billion. tradingview.com
Open questions
- Material 3 reports FY2026 revenue guidance of $5.13 billion‑$5.26 billion, which differs from the $5.21 billion‑$5.30 billion range in material 5.
Summary written by AlphAI AI Desk from 7 of 7 sources. Not investment advice. Figures are as stated by the linked sources.